BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gelbenegger G, Schoergenhofer C, Derhaschnig U, Buchtele N, Sillaber C, Fillitz M, Schenk TM, D'Sa S, Cartwright R, Gilbert JC, Jilma B, Jaeger U. Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program. Blood Adv 2020;4:997-1005. [PMID: 32176765 DOI: 10.1182/bloodadvances.2019001321] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Röth A. Do temperature and time matter in cold agglutinin disease? Blood 2020;136:380-1. [DOI: 10.1182/blood.2020006566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Gelbenegger G, Jaeger U, Fillitz M, D'sa S, Cartwright R, Shafer F, Wardecki M, Wang J, Schoergenhofer C, Jilma B. Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open‐label, extension trial. Br J Haematol. [DOI: 10.1111/bjh.18289] [Reference Citation Analysis]
3 Jalink M, de Boer ECW, Evers D, Havinga MQ, Vos JMI, Zeerleder S, de Haas M, Jongerius I. Halting targeted and collateral damage to red blood cells by the complement system. Semin Immunopathol 2021. [PMID: 34191092 DOI: 10.1007/s00281-021-00859-8] [Reference Citation Analysis]
4 Patriquin CJ, Pavenski K. O, wind, if winter comes … will symptoms be far behind?: Exploring the seasonality (or lack thereof) and management of cold agglutinin disease. Transfusion 2021. [PMID: 34893982 DOI: 10.1111/trf.16765] [Reference Citation Analysis]
5 Xiao Z, Murakhovskaya I. Development of New Drugs for Autoimmune Hemolytic Anemia. Pharmaceutics 2022;14:1035. [DOI: 10.3390/pharmaceutics14051035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Delvasto-Nuñez L, Jongerius I, Zeerleder S. It takes two to thrombosis: Hemolysis and complement. Blood Rev 2021;:100834. [PMID: 33985796 DOI: 10.1016/j.blre.2021.100834] [Reference Citation Analysis]
7 Michalak SS, Olewicz-Gawlik A, Rupa-Matysek J, Wolny-Rokicka E, Nowakowska E, Gil L. Autoimmune hemolytic anemia: current knowledge and perspectives. Immun Ageing 2020;17:38. [PMID: 33292368 DOI: 10.1186/s12979-020-00208-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Berentsen S. How I treat cold agglutinin disease. Blood 2021;137:1295-303. [PMID: 33512410 DOI: 10.1182/blood.2019003809] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
9 Berentsen S, Barcellini W, D'Sa S, Jilma B. Sutimlimab for treatment of cold agglutinin disease: why, how and for whom? Immunotherapy 2022. [PMID: 35946351 DOI: 10.2217/imt-2022-0085] [Reference Citation Analysis]
10 Murakhovskaya I. Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia. J Clin Med 2020;9:E4034. [PMID: 33322221 DOI: 10.3390/jcm9124034] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]